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Abstract
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Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and changes to
practice guidelines and dialysis payment systems have provided strong stimuli to decrease erythropoiesisstimulating agent use and increase intravenous iron administration in recent years. These factors have been
associated with a rise in iron utilization, particularly among hemodialysis patients, and an unprecedented
increase in serum ferritin concentrations. The mean serum ferritin concentration among United States
dialysis patients in 2013 exceeded 800 ng/ml, with 18% of patients exceeding 1200 ng/ml. Although these
changes are broad based, the wisdom of these practices is uncertain. Herein, we examine influences on and
trends in intravenous iron utilization and assess the clinical trial, epidemiologic, and experimental evidence
relevant to its safety and efficacy in the setting of maintenance dialysis. These data suggest a potential for
harm from increasing use of parenteral iron in dialysis-dependent patients. In the absence of well powered,
randomized clinical trials, available evidence will remain inadequate for making reliable conclusions about
the effect of a ubiquitous therapy on mortality or other outcomes of importance to dialysis patients.
Nephrology stakeholders have an urgent obligation to initiate well designed investigations of intravenous
iron in order to ensure the safety of the dialysis population.
Keywords: dialysis, ESRD, anemia, erythropoietin
Patients with ESRD receive numerous therapeutic interventions, yet the clinical benefits are often
questionable. The gold-standard proof of efficacy and safety is a properly planned and conducted
randomized controlled trial (RCT). Such trials are largely unavailable for hard clinical end points in
patients with ESRD, in whom most interventions are implemented based on extrapolation of results of
observational data, RCTs performed in other populations (e.g., treatment of hypertension or diabetes), or
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable
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RCTs demonstrating improvement in intermediate or surrogate end points, such as biochemical
abnormalities (e.g., hemoglobin, parathyroid hormone, or phosphorous).
Applying treatments without the benefit of conclusive evidence from RCTs is defensible. After all, lack of
proof of efficacy does not equal proof of lack of efficacy, and one can easily justify treatment based on
favorable observational data or compelling pathophysiologic links between the abnormalities and adverse
clinical outcomes. For decades, treatment in ESRD was shaped by this model of thinking, under the
assumption that the balance of risks and benefits would surely justify the interventions in question.
More recently, several RCTs suggested that erythropoiesis-stimulating agent (ESA) use could be harmful
and failed to confirm prior observational studies and cross-sectional analyses that had consistently shown
improved patient outcomes with higher achieved hemoglobin, thereby refuting widely held beliefs about
1 4
the benefits of anemia therapy. – The prospect of an entire generation of patients with ESRD being
exposed to potentially harmful effects of high-dose ESA had a chilling effect, with swift regulatory action
5
and consequent changes in clinical practice. The cautionary tale of ESA therapy has spotlighted other
ESRD interventions lacking sufficient RCT-based evidence of hard clinical benefits. Phosphate binder use,
secondary hyperparathyroidism therapies, novel arteriovenous fistula cannulation techniques, and changes
in duration and dose of dialytic technique have been implemented based on epidemiologic studies or
clinical trials powered on unvalidated surrogate end points and beliefs that their benefits would outweigh
6 8
9
theoretical risks. However, questions about efficacy – and safety will persist until dispelled by proper
evidence from RCTs.
Among the many treatments applied to correct biochemical abnormalities without proper evidence, use of
intravenous iron (IVI) for anemia is particularly important because its use in ESRD is rising and nearly
10
universal, and it epitomizes clinical equipoise based on equally plausible arguments suggesting potential
benefits and harm in the absence of definitive evidence from RCTs. Given the failure of RCTs to confirm
observational associations in the area of anemia, use of observational evidence and surrogate end points to
develop guideline statements is questionable and cannot adequately assure the safety of the IVI use now
dominant in the United States dialysis population.
In this article, we describe the background upon which IVI use has become ubiquitous, the pros and cons
of its application, and most importantly, why the practice of IVI use in ESRD more so than ever demands
well powered and properly conducted RCTs.

Secular Trends

Go to:

The introduction of epoetin in 1989 led to dramatic declines in transfusions and to higher hemoglobin
11 12
values in dialysis patients. , Mean hemoglobin increased from 9.6 g/dl in 1991 to 10.8 g/dl by 1997. The
1997 guidelines by the Dialysis Outcomes Quality Initiative (now the Kidney Diseases Outcomes Quality
Initiative [KDOQI]) recommended IVI to support a hemoglobin between 11 and 12 g/dl, maintain ferritin
13
between 100 and 800 ng/ml, and transferrin saturation (TSAT) between 20% and 50%. Both the 1997
and 2001 guidelines were opinion based given the absence of RCT evidence on long-term safety of
13 14
targeting higher hemoglobin and ferritin with ESAs or IVI. , However, they were a necessary attempt to
guide practice given imperfect data and, as described below, were associated with increased use of IVI.
11

Mean hemoglobin in hemodialysis patients increased from 11.0 g/dl in 1998 to 12.0 g/dl in 2005. Mean
ferritin was only 302 ng/ml in 1993, and 36% of patients had evidence of iron deficiency as evidenced by
15
serum ferritin <100 ng/ml. By 2001, when KDOQI raised the lower ferritin threshold further to 200
14 16
ng/ml, mean ferritin had risen to 526 ng/ml (Figure 1). , Mean ferritin reached 586 ng/ml in 2007 with
16
22% of patients >800 ng/ml. Subsequently, between 2006 and 2010, hemodialysis patients saw modest
17 19
declines in mean hemoglobin and ESA doses, whereas transfusion rates were unchanged. –
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These changes were spurred by several factors: reexamination of ESA safety issues first raised by the 1998
1 20
Normal Hematocrit Trial , ; the Correction of Hemoglobulin and Outcomes in Renal Insufficiency trial,
which demonstrated that targeting a higher hemoglobin with ESA was associated with increased risk of
3
death and cardiovascular events ; a 2007 US Food and Drug Administration (FDA) advisory
recommending more conservative ESA use; several analyses suggesting that higher ESA doses per se
21 23
mediated risk – ; and finally the 2009 Trial to Reduce Cardiovascular Events With Aranesp Therapy,
which reported that ESAs did not reduce cardiovascular events or deaths but increased thrombotic risks,
and possibly the risk in patients with cancer—a finding highlighted by the results of several oncology
2 24
trials. ,
More recently in 2011, the US Centers for Medicare and Medicaid Services instituted a partially capitated
payment system for dialysis services that included both ESAs and IVI, which were previously separately
25
billable. This provided financial incentives for dialysis providers to reduce utilization of high-cost items
26
like ESAs by increasing use of lower-cost IVI. Concurrently, the US FDA revised the ESA label,
cautioning against starting ESAs in patients with hemoglobin>10 g/dl, eliminating the 10–12 g/dl
5 27
hemoglobin target, and recommending the lowest ESA dose necessary to avoid transfusion. ,
These events were associated with declines in mean hemoglobin and ESA doses, increased transfusions,
18 28
increased IVI use, and increased iron stores. , Data from the Dialysis Outcomes and Practice Patterns
Study Practice Monitor showed a decrease in hemoglobin from 11.5 to 11.0 g/dl between August 2010 and
29
December 2011, and to 10.9 g/dl by December 2013. Mean weekly ESA dose declined from 19,700 to
29
10,800 U between August 2010 and December 2013. Conversely, mean ferritin increased from 640 to
29
826 ng/ml from August 2010 to January 2012 and remained stable through December 2013. Similarly,
29
the percentage of patients with ferritin >1200 ng/ml increased from 8.6% to 18% of patients.

Iron Deficiency
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Iron is an essential component of hemoglobin, myoglobin, and other enzymes involved in oxidation and
30
reduction. Absolute iron deficiency has been associated with wide-ranging systemic effects including
fatigue, glossitis, restless legs, and pica and may affect stamina in the absence of overt anemia. Most
significantly, sufficient iron availability during development of nascent reticulocytes is necessary for
complete hemoglobinization of red blood cells.
Iron deficiency will occur in most hemodialysis patients due to ongoing blood losses from the dialysis
14
circuit, gastrointestinal tract, laboratory testing, and procedures. In addition, inflammation increases
hepcidin, thereby reducing intestinal iron absorption and release of iron from stores—a process possibly
antagonized by secretion of erythroferrone, a recently identified hormone that appears to suppress hepcidin
31 33
secretion. – Trials have thus repeatedly shown oral iron to be ineffective at treating iron deficiency in
34
the setting of hemodialysis, which appears to be due to hepcidin-mediated blockade of iron absorption,
ongoing iron losses, and poor patient tolerance. Consequently, guidelines have repeatedly recommended
13 14 23
IVI in hemodialysis patients , , —a recommendation consistent with trials demonstrating that
22 35 36
administration of IVI increases hemoglobin and reduces ESA dose requirements, , , although whether
increasing hemoglobin or reducing ESA dose improves quality of life or reduces morbidity and mortality
is unknown.

Assessment of Iron Stores

Go to:
37

Ferritin and TSAT, the currently recommended tests to assess iron status in dialysis patients, have
limitations that make diagnosis of iron deficiency or overload challenging. Ferritin is a positive and
38
transferrin is a negative acute phase reactant. This is relevant because inflammation is highly prevalent in
39
the dialysis population. Ferritin, a marker of intracellular iron stores, also has sex differences and
40
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important interpersonal variability, whereas transferrin, the major iron-binding protein in circulation, is
affected by protein-energy wasting as well as diurnal variation.
41 43

Studies have shown that the sensitivity of the lower TSAT limit of <20% is low (59%–88%). –
Similarly, at a cut-off of ≤100 ng/ml, the sensitivity of ferritin is 35%–48% (validated against a functional
41 43
definition of increasing hemoglobin and/or decreasing ESA dose). , At ≤200 ng/ml, sensitivity is only
42
41% (validated against bone marrow biopsy). Thus, current indices perform poorly—only half of the
patients who will respond to additional IVI have a ferritin<100 and a TSAT≤20%, functional iron
deficiency, or reticuloendothelial blockade. This may explain why people with normal values of TSAT or
35
higher ferritin levels (500–1200 ng/ml) still respond to IVI.
Ferritin’s utility to detect iron overload faces similar challenges. Most hemodialysis patients receiving
44 45
ESA and IVI supplementation have excessive hepatic iron on magnetic resonance imaging. , In a study
that closely followed guidelines for ESA administration and iron supplementation, 80% of the patients had
45
excessive iron in the liver on magnetic resonance imaging and 30% had severe liver iron overload. A
2009 study including 96 hemodialysis patients using bone marrow biopsy showed that most patients with
ferritin levels of >500 ng/ml had higher levels of C-reactive protein and an increased content of bone
46
marrow iron. In short, the most widely used indices to assess iron stores are currently insufficient to
reliably distinguish patients likely to benefit from IVI from those with iron overload. Measurement of bone
marrow, hepatic, or myocardial iron stores may provide a means of distinguishing individuals likely to
benefit from additional IVI from those likely to be harmed. Similarly, serum hepcidin levels could help to
distinguish individuals likely to benefit from IVI versus those in whom alternative approaches (e.g.,
treatment of inflammation) are likely be safer or more effective. To date, the reproducibility and clinical
utility of these tools for preventing IVI complications remain theoretical and are yet to be established in
clinical studies.

Benefits of IVI

Go to:

It should be noted that the introduction of ESAs and IVI was broadly welcomed by the nephrology
community because the requirement for frequent transfusion in the pre-ESA era was associated with
important downsides, including iron overload, infections (especially hepatitis C), pretransplant
sensitization, and the occasional inability to safely transfuse highly immunized patients. However, whether
IVI treatment itself results in improved health is largely unknown. RCTs have not sufficiently evaluated
patient-centered outcomes such as mortality, hospitalization, or quality of life. By contrast, surrogate end
points such as hemoglobin or ESA dose have been extensively studied. There has also been some limited
47
evaluation of IVI for its effect on restless legs syndrome and other patient symptoms.
With respect to hemoglobin response and ESA dose reduction, the literature is rich and consistent in
finding treatment to be efficacious. The first published RCT comparing intravenous and oral iron in
48
hemodialysis patients found a 46% ESA dose reduction with intravenous therapy. Subsequent studies
have been very consistent in finding that regular (often weekly) doses of IVI reduce ESA requirements,
although there is less literature on peritoneal dialysis. Largely unanswered questions remain regarding how
much iron to administer, the optimal dosing regimen, and targets for iron status tests.
35

One important trial was the Dialysis Patients’ Response to IVI with Elevated Ferritin (DRIVE) study.
This study broke new ground by testing the efficacy of IVI when administered to individuals with serum
ferritin>500 ng/ml and TSAT≤25% and allowed enrollment of individuals with ferritin between 800 and
49 50
1200 ng/ml, a level typically used to exclude enrollment in previous IVI trials. , Randomization to IVI
resulted in an increase in hemoglobin compared with placebo. A follow-up observational study of DRIVE
participants demonstrated that IVI led to a significant reduction in ESA dose requirements and the cost of
36 51
anemia management. , The study extended previous knowledge by suggesting that IVI treatment
improves erythropoietic response to ESA therapy even with fairly high baseline ferritin, but the small
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable
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number of participants (n=134) and short duration preclude the ability to make definitive safety
conclusions.
It is clear that raising ferritin and TSAT with IVI reduces ESA doses and lowers costs, and it is possible
that increasing hemoglobin levels with more IVI and fewer ESAs improves outcomes. However, this has
not yet been tested in clinical trials, and improving hemoglobin levels in this manner may not actually be
beneficial. For example, increasing hemoglobin levels did not improve clinical outcomes in ESA treatment
studies (except in the treatment of severe anemia). By contrast, secondary analyses of trial data suggest
52
that higher ESA doses are associated with adverse cardiovascular outcomes, suggesting that using IVI to
reduce ESA doses could have important cardiovascular benefits. Although untested in a nephrology
setting, a recent cardiology study may be helpful in this regard. The Ferinject Assessment in Patients with
Iron Deficiency and Chronic Heart Failure study randomized 459 patients with congestive heart failure to
53
treatment with intravenous ferric carboxymaltose or placebo. After 24 weeks, improvements were found
in measures of functional status and quality of life in the IVI group. There was no significant difference in
mortality, but there was a trend toward fewer heart failure hospitalizations (P=0.08). Findings were similar
in the recent Cardiac Compass with Optivol to Negate Future Inpatient Re-Admissions through Monitoring
in HF Patients study, which randomized 304 patients with heart failure to ferric carboxymaltose or placebo
and demonstrated significant reductions in heart failure hospitalization (hazard ratio, 0.39; 95% confidence
54
interval [95% CI], 0.19 to 0.82; P=0.01). Extrapolation of these findings to hemodialysis patients is
difficult, but it does support the potential for important clinical benefits from IVI in the hemodialysis
population.
In summary, IVI-induced ESA dose reduction and hemoglobin increase may improve health outcomes, but
the putative benefits remain speculative and untested in RCTs. Until the effect of IVI in hemodialysis on
mortality, cardiovascular events, hospitalizations, quality of life, or other outcomes is better understood,
whether IVI treatment is actually beneficial will remain unknown. A study currently recruiting in the
United Kingdom (Proactive IV Iron Therapy in Haemodialysis Patients [PIVOTAL]) is powered for a
primary end point of time to all-cause death or a composite of nonfatal cardiovascular events and may
prove helpful in this regard. The PIVOTAL study will recruit 2080 patients from >50 sites and will
compare the effect of a proactive high-dose with a reactive low-dose regimen of iron sucrose in ESA55
treated hemodialysis patients with ferritin<400 µg/L and TSAT<30%. With a primary end point of time
to death or a composite of nonfatal cardiovascular events and secondary end points that include infection
and infectious hospitalizations, it is expected that the results will provide crucial insights into the true
clinical benefits of IVI in the setting of hemodialysis.

Pharmacology of IVI

Go to:

Early IVI compounds were formulated as inorganic iron oxyhydroxide complexes but were highly toxic
56
with high incidences of severe hypotension. Currently available formulations surround the iron
oxyhydroxide core with carbohydrate shells of different sizes and polysaccharide branch characteristics
57 58
and are considered nanoparticles (Table 1). ,
Pharmacokinetic analysis of IVI complexes is limited by difficulties in distinguishing IVI formulations
from endogenous iron without radiolabeling. Nevertheless, the carbohydrate shell clearly determines the
58
relative uptake by endothelial and lymphatic cells as well as the reticuloendothelial system (RES). This
results in longer plasma residence times with higher doses, especially with larger molecular weight
59 60
formulations. , Thus, doses above the RES capacity will remain circulating until the concentration falls
below the capacity limit, at which point the pharmacokinetics become linear or concentration independent.
Given their complexity, these agents have not been sufficiently studied with regard to comparative
biodistribution, metabolic fate, and potential extracellular and intracellular toxicity.

In Vitro Safety Signals
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable
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The transient release of labile iron directly into plasma (i.e., before metabolism by RES) is more likely
with smaller carbohydrate shells and results in transient concentrations of labile plasma iron and formation
of highly reactive free radicals such as the hydroxyl radical that uniquely limits the maximum dose that
61 63
can be administered with each formulation (Table 2). – Not surprisingly, IVI formulations have been
shown to induce oxidative stress, inflammation and cellular toxicity, pro-oxidant cell signaling, tissue
inflammation, cellular iron deposition, and cytotoxicity in cell culture models, animal models, and acutely
63 67
in human participants – with more labile compounds inducing more toxicity than those with larger
68 69
carbohydrate shells. , IVI has also been associated with immune dysfunction, augmentation of bacterial
67 69 71
growth, and increased Gram-positive bacteria growth in vitro. , – Taken collectively, these studies
underscore the need for comprehensive clinical and translational investigations to evaluate the effect of
differences in formulation, pharmacokinetic, and pharmacodynamic characteristics and to determine
whether repeated induction of oxidative stress from IVI has long-term sequelae.

Safety Signals in Clinical Trials

Go to:

Although well powered studies of sufficient duration are not yet available, examination of previously
reported studies, even without the power or duration of necessary follow-up, provide at least a cursory
understanding for whether any safety signal is present with IVI treatment. The easiest adverse effect of IVI
to assess is anaphylaxis, because of its immediacy and severity. The most helpful study in this regard was
reported by Michael et al. A total of 2534 hemodialysis patients were directly observed after double-blind
50
exposure to intravenous sodium ferric gluconate (SFGC) or placebo. One patient in each of the SFGC
and placebo groups experienced anaphylactoid reactions. Additional cases with characteristics possibly
consistent with anaphylaxis occurred in 0.4% of intravenous SFGC–treated patients and 0.1% of placebotreated patients. The results suggest that there is a relatively low rate of anaphylaxis with nondextran irons
and that the reactions are generally easily managed. Relatively large, but nonrandomized, clinical trials are
49
consistent with a similar safety profile for iron sucrose therapy, although this and other studies have been
less helpful for assessing anaphylaxis due to the lack of placebo controls, direct observation, underreporting, or use of inappropriate data sources to assess end points.
It is more difficult to assess long-term safety although some information on end-organ effects,
cardiovascular events, and infection risk can be gleaned from available clinical trials, with the
understanding that they were underpowered or had insufficient duration of follow-up for reliable
conclusions. For example, in the recently reported Ferinject assessment in patients with Iron Deficiency
Anemia and Non-Dialysis–Dependent Chronic Kidney Disease (FIND-CKD) study, 626 patients with
predialysis CKD were treated with intravenous ferric carboxymaltose (with a high and low ferritin target)
or oral iron for 52 weeks. The percentage of deaths, myocardial infarctions, and infections was not
significantly different between oral iron–treated and IVI-treated patients. However, the study was not
72
powered for safety. Similarly, a 2008 meta-analysis comparing IVI to oral iron by Rozen-Zvi et al.
34
included seven dialysis studies, but only one had >100 patients and none had treatment periods >6
months. The authors noted additionally that data related to safety (mortality rate) were sparse. Finally, the
6-week DRIVE trial and its 6-week follow-up DRIVE II trial randomized only 57 participants with
35 36
ferritin>800 ng/ml. , Taken together, we would conclude that the clinical trial literature on IVI in
hemodialysis has insufficient patients followed for an insufficient length of time to fully assess the longterm safety of IVI treatment, particularly when used in individuals with serum ferritin>800 ng/ml.

Safety Signals in Epidemiology Studies

Go to:

Observational studies provide an important alternative to RCTs for assessing the safety of IVI, despite a
greater susceptibility to confounding and bias. A 2002 study by Feldman et al. used the US Renal Data
System (USRDS) Dialysis Morbidity and Mortality Studies waves 1, 3, and 4 to analyze the safety of IVI.
Among 10,169 patients, those with bills submitted for >10 vials of iron dextran over a 6-month period
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable
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were found to have increased risks of death (adjusted relative risk, 1.11; 95% CI, 1.00 to 1.24) and
73
hospitalization (adjusted relative risk, 1.12; 95% CI, 1.01 to 1.25) than those without any submitted bills.
A subsequent analysis of 32,566 Fresenius Inc. hemodialysis patients by the same authors did not confirm
an association between IVI dose and risk of death after adjusting for time-varying measures of iron
74
treatment and fixed and time-varying measures of morbidity, whereas a study by Kaysen et al. of 59,840
75
prevalent hemodialysis patients found that use of IVI was associated with a 22% reduction in mortality.
More recently, Kalantar-Zadeh et al. studied 58,058 DaVita Inc. dialysis patients. For patients who
received <400 mg of IVI per month, the risk for death was found to be lower compared with patients with
no IVI administered. By contrast, doses>400 mg per month were associated with increased risks of
76
death. Subsequently, Kshirsagar et al. studied 117,050 hemodialysis patients. No association was found
77
between dose of IVI and short-term risk of myocardial infarction, stroke, or death. By contrast, a much
smaller observational study found dose-related increases in risks of cardiovascular events and death with
78
intravenous ferric chloride hexahydrate—a product not currently in use in the United States.
The relationship between IVI and infection is another area of interest. Previously published studies have
had mixed results. A prospective observational study by Hoen et al. followed 988 hemodialysis patients
from 19 French centers for 6 months. There were 51 episodes of bacteremia, but no association with either
79
IVI dosing or serum ferritin concentration was detected. Brookhart et al. recently used DaVita data to
study 117,050 hemodialysis patients. Patients with higher compared with lower doses had a slightly but
significantly greater risk of infection-related hospitalization or death (hazard ratio, 1.05; 95% CI, 1.02 to
1.08), whereas individuals with the combination of high serum ferritin and high iron saturations at baseline
had the highest risk of infection-related hospitalizations. Brookhart et al. also found that compared with
maintenance therapy, bolus treatment was associated with a greater risk of infection (risk difference, 25
80
additional events per 1000 patient-years; 95% CI, 16 to 33).
On balance, these studies have conflicting signals and do not establish a clear relationship between IVI
dosing and mortality. Better studies of the associations of outcomes, particularly infection, with dose and
pattern of administration are clearly needed. Dose-related safety information is particularly necessary
given that the above studies analyzed data partly or wholly predating contemporary increases in serum
29
ferritin and iron utilization. For example, >75% of participants in the study by Brookhart et al. had
80
baseline ferritin <700 ng/ml. To our knowledge, the long-term effect of IVI administration to patients
with elevated baseline serum ferritin levels upon surrogate markers of atherosclerosis, immune function,
inflammation, and vascular reactivity also remain unstudied. However, a recent study in which 19 of 21
(90.5%) long-term dialysis patients with serum ferritin>1000 ng/ml had evidence of increased oxidative
44
stress as well as splenic and hepatic tissue iron overload suggests caution.

Clinical Ramifications

Go to:

As reviewed above, clinical trials have failed to study the long-term consequences of contemporary IVI
81
utilization, whereas epidemiologic studies raise questions regarding effects on mortality, cardiovascular
outcomes, infections, and tissue deposition, and in vitro experiments support the notion that IVI
78 82
exacerbates oxidative stress, inflammation, and endothelial dysfunction. , Despite clear clinical
ramifications, data remain insufficient to make firm recommendations regarding the maximum single,
weekly, or cumulative dose of IVI or to support a particular limit of iron indices above which iron
administration is clearly contraindicated. Given current levels of exposure to IVI, these data raise the
possibility of large-scale harm to dialysis patients from current practices. However, it remains unclear
whether reducing IVI use would actually improve cardiovascular or infectious outcomes or conversely
whether it would potentially increase transfusion rates, thereby resulting in harm. In short, there is
compelling public health rationale for prioritizing a judicious examination of risk versus benefits of IVI.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable
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The escalating trends in IVI use should also make one consider the pressures that drive changes in
prescribing behavior in dialysis care. Guidelines and clinical judgements driven by ESA trials have
stimulated decreased ESA with broader utilization of IVI for ESA sparing. Coupled with payment
pressures (particularly given beliefs that because adverse events associated with IVI are rare, high-dose
83
IVI would be innocuous ), these concerns have driven practices that have not undergone proper safety
evaluation. These factors are especially prominent with IVI, but they are hardly unique and are arguably
broadly representative of the influences on ESRD care.
The case of IVI thus appears to represent an undesirable paradigm in which initial studies and an imperfect
evidence base without appropriate RCTs and guideline-based practices (potentially not appropriate for
individual patients) have converged with financial incentives to dialysis units, Medicare quality
parameters, and the potential for rapid adoption given the dominance of large and medium dialysis
organizations to quickly drive drug utilization well beyond the space in which the risk versus benefit ratio
has been adequately defined. Caution is needed, especially (although not exclusively) in anemia
management, in which recent definitive RCTs had divergent results from earlier, encouraging
1 4 84
observational studies. , , Performing the needed studies to define best practices may represent an
opportunity to not only redefine utilization of IVI but to also transform the overall model of ESRD care.

Recommendations

Go to:

There is considerable uncertainty regarding whether contemporary patterns of IVI utilization result in
improved patient-level outcomes and not just an improvement in anemia. Although analysis of large
85
databases provides the best means of detecting rare adverse effects of IVI, the current situation provides
urgent justification for ESRD stakeholders to fund the large RCTs designed to provide gold-standard
answers to basic safety questions about a widely used therapy.
55

The highest priority should be given to RCTs, like the PIVOTAL study, that are designed to compare the
effect of conservative and liberal strategies of IVI administration, to compare the safety of bolus and
maintenance dosing strategies, and to understand the utility of standard or novel biomarkers of iron stores
for detecting iron deficiency and avoiding iron overload and iron-related morbidity in hemodialysis (
Table 3). These trials must be powered to detect differences in mortality, cardiovascular events, infections,
and hospitalizations. Given the larger size of the hemodialysis population as well as the greater losses of
blood and higher utilization of iron in hemodialysis compared with peritoneal dialysis, priority should be
given to studies of the hemodialysis population. Nevertheless, similar considerations apply peritoneal
dialysis, and studies in this population may also be necessary.
The joint influences of inadequate studies, practice guidelines, the delivery of care in large organizations,
and strong financial incentives to these organizations have at times driven dialysis care in directions that
may have harmed generations of patients with ESRD. Changes in iron utilization represent yet another
predictable outcome of those influences. The uncertain safety presents the nephrology community with a
critical opportunity to demand RCTs with patient-level outcomes and to ensure that there is adequate
science in this and other areas of dialysis practice to make evidence-based practice the primary
determinant of our treatment algorithms and to fully realize our ethical and professional obligations to
provide safe and effective care to our patients.
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Figure 1.

Trends in mean serum ferritin over time. Data sources include the ESRD Core Indicators Project, the USRDS, the Dialysis
Outcomes Practices Patterns Study, the Network 11 ELab Project, and the Medicare Clinical Performance Measure
13 15 16 86
Reports. , , , IV, intravenous.
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Table 1.
Physiochemical characteristics and pharmacokinetics of IVI formulations
Properties

Ferumoxytol

Ferric

Iron Dextran

Iron Sucrose

Carboxy

Ferric
Gluconate

Maltose
Molecular mass (D)

731,000

150,000

410,000

252,000

200,000

Carbohydrate shell

Polyglucose

Carboxymaltose

Dextran

Sucrose

Gluconate,

sorbitol

polysaccharide

loosely

carboxymethylether

associated
sucrose

Median shell/particle
diameter
(nm)
Properties
Relative catalytic iron

26.3

23.1

12.2

8.3

8.6

Ferumoxytol

Ferric

Iron Dextran

Iron Sucrose

Ferric

+

+
Carboxy

++

+++

+++
Gluconate

release
Relative stability of

Maltose
High

High

High

Medium

Low

Relative osmolality

Isotonic

Isotonic

Isotonic

Hypertonic

Hypertonic

Administration (iv

30 mg/s

Bolus push

50 mg (1

Approximately

12.5 mg/min

ml)/min

20 mg/min

5–20

6

elemental iron within
the carbohydrate shell

push) rates
t1/2 (h)

Approximately 15

7–12

Approximately
1

D, daltons; nm, nanometer; iv, intravenous.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable

18/20

5/17/2018

Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis

Table 2.
FDA approval and dosing of currently approved IVI formulations
Drug (Trade
Name)

Year

Test Dose

Maximum

Off–

Approved Necessary

Approved

Label

Single

Dosing

Iron Repletion Dose

Miscellaneous

1g

Equipment to respond

Dose
Low molecular

25 mg

100 mg

1g

weight iron

over

over 30 s

over

to anaphylaxis

dextran
87
(InFed)

15–30

4–6 h

required

High molecular

1992

min
1996

weight iron
88 89
,
dextran

25 mg

100 mg

1g

over

over 30 s

over

Europe; use

4–6 h

discouraged due to

15–30

1g

min

Not available in

high incidence of
reactions

Drug (Trade
Sodium
ferric
Name)
gluconate
90
(Ferrlecit)
Generic:

Year
TestNo
Dose 125
Maximum
1999
mg iv
Approved Necessary push
Approved
over
Single
10 min
Dose

2011

Ferumoxytol
92 93
,
(Feraheme)

Iron
125
mgRepletion
at each Dose

Miscellaneous
—

hemodialysis session×8

Dosing
push
over
15 min

Nulecit
Iron Sucrose
91
(Venofer)

Off–
250
Label
mg iv

2000

2009

No

No

200 mg iv

300

100 mg iv at 10

push over

mg iv

consecutive or 200 mg

2–5 min

over 1

iv at 5 consecutive

h

hemodialysis sessions

—

510 mg×2 doses over 2

510 mg iv
push over

—

—

different visits

<1 min
Ferric

2013

No

750 mg

carboxymaltose

slow push

(Injectafer,
94
Ferinject)

or infusion

—

750 mg×2 over 1 wk

over 15
min

Dashed-lines indicate non-applicable items.

https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4446883/?report=printable

19/20

5/17/2018

Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis

Table 3.
Research recommendations
Comparison

Priority Recommended

Major End points

Design
Conservative versus liberal dosing

+++

RCT

strategies
Bolus versus maintenance dosing

Mortality, infection, nonfatal CV end
points

+++

RCT

Mortality, infection, nonfatal CV end
points

High versus low ferritin threshold for IVI

+++

RCT

administration
Ferritin versus TSAT versus novel iron

points, end-organ damage
+

biomarkers
ESA sparing versus IVI sparing versus

TRS, RCT, or

++

RCT

Comparison

Mortality, infection, nonfatal CV end
points, quality of life

+

TRS, RCT

formulations
Comparison of IVI formulation/brand

Iron overload, end-organ damage

PCS

hemoglobin sparing strategies
IVI versus standard or novel oral iron

Mortality, infection, nonfatal CV end

Mortality, infection, nonfatal CV end
points, quality of life, anemia, ESA dose

+

RCT

Priority Recommended

Mortality, infection, nonfatal CV end
points, anemia end points, ESA dose
Major End points

Design
TRS, translational research study; PCS, prospective cohort study; CV, cardiovascular.
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